Palforzia Purple Book BLA 125696

BLA number
125696
Proprietary names
Palforzia
Proper names
Peanut (Arachis hypogaea) Allergen Powder-dnfp
Applicant
Greer Laboratories, Inc.
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001PalforziaPeanut (Arachis hypogaea) Allergen Powder-dnfp351(a)0.5MGPowderOralCapsuleRxLicensed2020-01-31
002PalforziaPeanut (Arachis hypogaea) Allergen Powder-dnfp351(a)1MGPowderOralCapsuleRxLicensed2020-01-31
003PalforziaPeanut (Arachis hypogaea) Allergen Powder-dnfp351(a)10MGPowderOralCapsuleRxLicensed2020-01-31
004PalforziaPeanut (Arachis hypogaea) Allergen Powder-dnfp351(a)20MGPowderOralCapsuleRxLicensed2020-01-31
005PalforziaPeanut (Arachis hypogaea) Allergen Powder-dnfp351(a)100MGPowderOralCapsuleRxLicensed2020-01-31
006PalforziaPeanut (Arachis hypogaea) Allergen Powder-dnfp351(a)300MGPowderOralSachetRxLicensed2020-01-31

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2025-03-01U001Palforzia351(a)RxGreer Laboratories, Inc.
2025-03-01U002Palforzia351(a)RxGreer Laboratories, Inc.
2025-03-01U003Palforzia351(a)RxGreer Laboratories, Inc.
2025-03-01U004Palforzia351(a)RxGreer Laboratories, Inc.
2025-03-01U005Palforzia351(a)RxGreer Laboratories, Inc.
2025-03-01U006Palforzia351(a)RxGreer Laboratories, Inc.
2022-05-01U001Palforzia351(a)RxAimmune Therapeutics, Inc.
2022-05-01U002Palforzia351(a)RxAimmune Therapeutics, Inc.
2022-05-01U003Palforzia351(a)RxAimmune Therapeutics, Inc.
2022-05-01U004Palforzia351(a)RxAimmune Therapeutics, Inc.
2022-05-01U005Palforzia351(a)RxAimmune Therapeutics, Inc.
2022-05-01U006Palforzia351(a)RxAimmune Therapeutics, Inc.
2021-05-01U001Palforzia351(a)RxAimmune Therapeutics, Inc.
2021-05-01N002Palforzia351(a)RxAimmune Therapeutics, Inc.
2021-05-01N003Palforzia351(a)RxAimmune Therapeutics, Inc.
2021-05-01N004Palforzia351(a)RxAimmune Therapeutics, Inc.
2021-05-01N005Palforzia351(a)RxAimmune Therapeutics, Inc.
2021-05-01N006Palforzia351(a)RxAimmune Therapeutics, Inc.
2020-08-01N001Palforzia351(a)RxAimmune Therapeutics, Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2022-05-01001Palforzia351(a)RxLicensed2020-01-31
2022-05-01002Palforzia351(a)RxLicensed2020-01-31
2022-05-01003Palforzia351(a)RxLicensed2020-01-31
2022-05-01004Palforzia351(a)RxLicensed2020-01-31
2022-05-01005Palforzia351(a)RxLicensed2020-01-31
2022-05-01006Palforzia351(a)RxLicensed2020-01-31
2021-05-01002Palforzia351(a)RxLicensed2020-01-31
2021-05-01003Palforzia351(a)RxLicensed2020-01-31
2021-05-01004Palforzia351(a)RxLicensed2020-01-31
2021-05-01005Palforzia351(a)RxLicensed2020-01-31
2021-05-01006Palforzia351(a)RxLicensed2020-01-31
2020-08-01001Palforzia351(a)RxLicensed2020-01-31